Table 2. Median PFS in previous trials with older adults.

Trial	Patient population	Median PFS
MRFOCUS215	‘Non-fit’ older or frail mCRC patients receiving upfront dose reduction	Median PFS was 3.5, 5.8, 5.2 and 5.8 months in the 5-FU monotherapy, FOLFOX, capecitabine monotherapy and CAPOX groups, respectively; a reasonable estimate for all patients is 5 months
AVEX33	Older mCRC patients, no candidate for oxaliplatin or irinotecan	Median PFS 9.1 months for capecitabine+bevacizumab, 5.1 months for capecitabine monotherapy.
NORDIC916	‘Non-fit’ older mCRC patients	Median PFS 5.1 months for full-dose S-1, 6.2 months for reduced-dose oxaliplatin+S-1. 25% received bevacizumab.
SALTO34	mCRC patients with median age 73 years (not specifically older patients)	Median PFS 8.2 months for capecitabine monotherapy, 8.4 months for S-1 monotherapy.

AVEXAVastin in the Elderly with XelodaCAPOXcapecitabine plus oxaliplatinFOLFOXfolinic acid, fluorouracil, and oxaliplatin5-FUFluorouracilmCRC, metastatic colorectal cancerPFSprogression-free survival